Abstract
Chapter provides background information useful in fully understanding how and why cytochrome P450 (CYP) in vitro methods and protocols are important in a modern drug discovery pipeline. We describe the organizational structure and the research activities within a typical pharmaceutical drug discovery and development company. The types of drug metabolism and pharmacokinetics (DMPK) and its drug disposition (ADME) properties, including in silico computational methods, in vitro ADME tests, and in vivo whole-animal models, are discussed and how these assays are being developed and applied to rational drug design. We discuss the interrelationship between drug physiology and pharmacology and how this interplay is used to develop DMPK assays. We suggest assay strategies for utilizing CYP in vitro methods and protocols, and finally, we discuss the future outlook for DMPK approaches in drug discovery. Chapter 2 provides comprehensive information concerning CYP enzymes and their related metabolism properties on xenobiotics, while Chapters 3–22 provide detailed CYP and non-CYP in vitro methods and protocols that can be easily established in a drug discovery pipeline.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Caldwell GW, Yan Z, Masucci JA, Hageman W, Leo G, Ritchie DM (2003) Applied pharmacokinetics in drug development: an overview of drug discovery. Pharmaceut Develop Regul 1(2):117–132
Berry IR, Martin RP (2008) The pharmaceutical regulatory process, 2nd edn. Informa Healthcare, New York
Ng R (2015) Drugs: from discovery to approval, 3rd edn. John Wiley & Sons Inc., New York
US Department of Health and Human Services. US Food and Drug Administration (FDA). http://www.fda.gov/ Drugs/Development Approval Process/How Drugs are Developed and Approved/Drug and Biologic Approval Reports/AND A Generic Drug Approvals/default.htm. Accessed 19 June 2020
Munos B (2009) Lessons for 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8(12):959–968
Eder J, Sedrani R, Wiesmann C (2014) The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 13(8):577–587
Paul SM, Mytelka DS, Dunwiddie CT et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203–214
Caldwell J (1996) The role of drug metabolism in drug discovery and development: opportunities to enhance time- and cost-efficiency. Pharm Sci 2:117–119
Chen KJ, Lee JC (2008) Establishment of high throughput screening (HTS) for drug discovery. Huaxue 66(4):269–277
Caldwell GW (2015) In silico tools used for compound selection during target-based drug discovery/development. Expert Opin Drug Discovery 10(7):1–23
Caldwell GW (2000) Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physicochemical, in vitro, and in vivo screens. Curr Opin Drug Discov 3:30–41
Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z (2001) The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top Med Chem 1(5):353–366
Caldwell GW, Yan Z (2009) ADME optimization and toxicity assessment in early- and late-phase drug discovery. Curr Top Med Chem 9(11):965–980
Caldwell GW (2016) ADME optimization and toxicity assessment in drug discovery. Front Med Chem 8(1):3–60
Yan Z, Caldwell GW (eds) (2004) Optimization in drug discovery: in vitro methods, 1st edn. Humana Press, Totowa, NJ
Caldwell GW, Yan Z (eds) (2014) Optimization in drug discovery: in vitro methods, 2nd edn. Humana Press, Totowa, NJ
Hall JE, Hall ME (2021) Guyton and hall textbook of medical physiology, 14th edn. Elsevier, Philadelphia, Pennsylvanian
Kenakin T (2016) Pharmacology in drug discovery and development, 2nd edn. Elsevier, Philadelphia, Pennsylvania
Di L, Fish PV, Mano T (2012) Bridging solubility between drug discovery and development. Drug Discov Today 17(9–10):486–495
Castro P, Madureira R, Sarmento B, Pintado M (2015) Tissue-based in vitro and ex vivo models for buccal permeability studies. In: Sarmento B (ed) Concepts and models for drug permeability studies-cell and tissue based in vitro culture models. Elsevier, Philadelphia, Pennsylvania, pp 189–202
Carstensen JT, Rhodes CT (eds) (2007) Drug stability, revised, and expanded. CRC Press, Boca Raton. https://doi.org/10.1201/9780367801298
Caldwell GW, Hasting B, Masucci JA, Yan Z (2014) Small molecule formulation screening strategies in drug discovery. In: Caldwell GW, Yan Z (eds) Optimization in drug discovery: in vitro methods, 2nd edn. Humana Press, Totowa, NJ, pp 1–20
Caldwell GW, Ferguson C, Buerger R, Kulp L, Yan Z (2014) Permeability assessment using 5-day cultured caco-2 cell monolayers. In: Caldwell GW, Yan Z (eds) Optimization in drug discovery: in vitro methods, 2nd edn. Humana Press, Totowa, NJ, pp 49–76
Yan Z, Caldwell GW (2001) Metabolism profiling and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 1(5):403–425
Cohen MS, Forrest ML (2011) Lymphatic drug delivery: therapy, imaging, and nanotechnology. Adv Drug Deliv Rev 63(10–11):865–866
Coe KJ, Koudriakova T (2014) Metabolic stability assessed by liver microsomes and hepatocytes. In: Caldwell GW, Yan Z (eds) Optimization in drug discovery: in vitro methods, 2nd edn. Humana Press, Totowa, NJ, pp 87–99
Lombardo F, Obach RS, Shalaeva MY et al (2002) Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 45:2867–2876
Caldwell GW, Masucci JA, Yan Z, Hageman W (2004) Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data. Eur J Drug Metabol Pharmacol 29(2):133–143
Pang SK, Durk MR (2010) Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism, and excretion. J Pharmacokinet Pharmacodyn 37(6):591–615
Ashauer R, Agatz A, Albert C et al (2011) Toxicokinetic-toxicodynamic modeling of quantal and graded sublethal endpoints: a brief discussion of concepts. Environ Toxicol Chem 30(11):2519–2524
Yan Z, Caldwell GW (2003) Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases. Eur J Drug Metabol Pharmacol 28(3):223–232
Caldwell GW, Masucci JA, Chacon E (1999) High throughput liquid chromatography-mass spectrometry assessment of the metabolic activity of commercially available hepatocytes from 96-well plates. Comb Chem High Throughput Screen 2(1):39–51
Cerny MA (2016) Prevalence of non-cytochrome P450–mediated metabolism in food and drug administration–approved oral and intravenous drugs: 2006–2015. Drug Metab Dispos 44:1246–1252
Yan Z, Rafferty B, Caldwell GW, Masucci JA (2002) Rapidly distinguishing reversible and irreversible Cyp450 inhibitors by using fluorometric kinetic measurements. Eur J Drug Metabol Pharmacol 27(4):281–287
Caldwell GW, Yan Z, Lang W, Masucci JA (2012) The IC50 concept revisited. Curr Top Med Chem 12:1282–1290
Yan Z, Caldwell GW (2013) In vitro identification of cytochrome P450 enzymes responsible for drug metabolism. Methods Mol Biol 1015:251–261
Argikar UA, Potter PM, Hutzler JM, Marathe PH (2016) Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J 18(6):1391–1405
Dasgupta M, Tang W, Caldwell GW, Yan Z (2010) Use of stable isotopic-labeled probes to facilitate LC/MS-based high throughput screening of time-dependent CYP inhibitors. Rapid Commun Mass Spectrom 24:2177–2185
Yan Z, Caldwell GW (2012) The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions. Curr Top Med Chem 12(11):1291–1297
Yan Z, Caldwell GW (2004) Stable-isotope trapping and rapid identification of reactive metabolites using the isotope MS signature. Anal Chem 76(23):6835–6847
Caldwell GW, Yan Z (2006) Screening for reactive intermediates and toxicity assessment in drug discovery. Curr Top Med Chem 9(1):47–60
Yan Z, Caldwell GW, Maher N (2008) Unbiased high-throughput screening of reactive metabolites on the linear ion trap mass spectrometer using polarity switch and mass tag triggered data-dependent acquisition. Anal Chem 80(16):6410–6422
Caldwell GW (2017) Can untargeted metabolomics be utilized in discovery/development? Curr Top Med Chem 17(24):2716–2739
Fernandes S, Cassani M, Pagliari S, Filipensky P, Cavalieri F, Forte G (2020) Tumor in 3D: in vitro complex cellular models to improve nanodrugs cancer therapy. Curr Med Chem 27(42):7234–7255. https://doi.org/10.2174/0929867327666200625151134
Bein A, Shin W, Jalili-Firoozinezhad S, Park MH, Sontheimer-Phelps A, Tovaglieri A, Chalkiadaki A, Kim HJ, Ingber DE (2018) Microfluidic organ-on-a-chip models of human intestine. Cell Mol Gastroenterol Hepatol 5(4):659–668
Shi S (2014) Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab 15(3):271–290
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Yan, Z., Caldwell, G.W. (2021). Cytochrome P450: In Vitro Methods and Protocols. In: Yan, Z., Caldwell, G.W. (eds) Cytochrome P450. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1542-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1542-3_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1541-6
Online ISBN: 978-1-0716-1542-3
eBook Packages: Springer Protocols